Renaissance Technologies’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-10,300
Closed -$110K 3790
2020
Q2
$110K Buy
+10,300
New +$101K ﹤0.01% 3262
2018
Q3
Sell
-6,900
Closed -$205K 3627
2018
Q2
$205K Buy
6,900
+340
+5% +$10.4K ﹤0.01% 3070
2018
Q1
$230K Buy
6,560
+1,300
+25% +$54.1K ﹤0.01% 3149
2017
Q4
$227K Buy
+5,260
New +$263K ﹤0.01% 3097

Other funds holding CYAD

Renaissance Technologies's CYAD Position: Q3 2020 in Review

Renaissance Technologies sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q3 2020, closing a stake of 10,300 shares — an estimated $110K sold.

Renaissance Technologies first reported a position in CYAD in Q4 2017 and held it in 4 quarters. The position peaked at $230K in Q1 2018. 7 funds tracked by Wall St. Rank hold CYAD as of Q3 2020.

  • Renaissance Technologies reported no remaining Celyad Oncology SA American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • Renaissance Technologies sold 10,300 Celyad Oncology SA American Depositary Shares shares in Q3 2020, an estimated $110K.
  • Renaissance Technologies first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2017 and held it in 4 quarters.
  • Renaissance Technologies's Celyad Oncology SA American Depositary Shares position peaked at $230K in Q1 2018.
  • 7 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q3 2020.

Based on Renaissance Technologies's 13F filing for Q3 2020, filed 13 Nov 2020.